ARCC Conference 2013

Dr. Scott Berry, MD, MHSc, FRCPC

Dr. Berry is a medical oncologist at Sunnybrook Odette Cancer Centre and an Associate Professor in the Faculty of Medicine at the University of Toronto. He completed his general medical training and medical oncology training at the University of Toronto. Dr. Berry is an active participant in colorectal cancer research. He has also authored several prostate cancer and colorectal cancer guidelines for the Cancer Care Ontario Program in Evidence Based Care and chaired national consensus guideline meetings for the Colorectal Cancer Association of Canada. Dr. Berry loves teaching and is the Program Director for the Medical Oncology Training Program at the University of Toronto. He also chairs the Royal College of Physicians and Surgeons of Canada Specialty Committee for Medical Oncology and is Co-Medical Director of oncology education. His other academic interest is the bioethical issues surrounding the care of people with cancer, in particular the ethical issues surrounding funding new and expensive cancer medications. Dr. Berry has a Masters degree in bioethics from the University of Toronto. He has also served on the ASCO Ethics Committee and is the Ethics Advisor to the pan-Canadian Oncology Drug Review and the NCIC Data Safety Monitoring Committee

Dr. Heather Bryant, MD, PhD, CCFP, FRCPC

Dr. Bryant is Vice President of Cancer Control for the Canadian Partnership Against Cancer (CPAC), an organization funded by the federal government to implement the national cancer control strategy across Canada. Dr. Bryant joined CPAC in January 2008 from the Alberta Cancer Board, where she was Vice President and Chief Information Officer and Director of the Division of Population Health and Information. Dr. Bryant studied medicine at the University of Calgary and took her first residency certification in family medicine. She followed this with a fellowship in community medicine and a PhD in epidemiology. Dr. Bryant has been active on many national committees and chaired the National Committee for the Canadian Breast Cancer Screening Initiative (Health Canada), the Joint Advisory Committee on Cancer Control (National Cancer Institute of Canada), the Population Health Committee (Medical Research Council), and was Inaugural Chair of the Institute Advisory Board for Cancer for the Canadian Institutes for Health Research. She was elected to the Board of the Union for International Cancer Control in 2012. Dr. Bryant is also a Clinical Professor in the Departments of Community Health Sciences and Oncology at the University of Calgary.

Dr. Nadine Caron, MD, MPH, FRCSC

Dr. Nadine CaronDr. Caron is a General and Endocrine surgeon at the University Hospital of Northern British Columbia. She is an Assistant Professor, Surgery at the University of British Columbia, Northern Medical Program and an Associate Faculty member at the Johns Hopkins University Bloomberg School of Public Health’s Center for American Indian Health. As the first female First Nations student to graduate from the University of British Columbia’s medical school, she won the Hamber Gold Medal as the top graduating student and was named one of Maclean’s “One Hundred Canadians to Watch.” During her surgical residency, she completed her Master’s degree in Public Health from Harvard University and was awarded UBC’s Top Student Award. Passionate about Aboriginal health and Canadian health policy, she serves on numerous committees including the Governing Council for the Canadian Institutes of Health Research, the Board of Directors of the Michael Smith Foundation for Health Research and played a key role in the Royal College of Physicians and Surgeons of Canada/Indigenous Physicians Association of Canada committee that developed culturally competent curricula for post-graduated medical education (Chair of Surgery Curriculum Development). Through her role modeling, speaking engagements and formal committees, Dr. Caron aims to share her passion and foster ongoing opportunities to eliminate health disparities in Indigenous communities in both Canada and beyond our borders.

Dr. Ruth Etzioni, PhD

Dr. Etzioni is a biostatistician who specializes in the modeling cancer progression and outcomes. For the last ten years she has modeled prostate cancer detection and treatment with the goal of identifying the benefits and harms of prostate cancer screening and developing population screening policies. Dr. Etzioni serves or has served on several national prostate cancer policy panels including the American Cancer Society’s panel for the early detection of prostate cancer, the National Comprehensive Cancer Network, and the American Urology Association’s PSA panel. She has been a faculty member at the Fred Hutchinson Cancer Research Center since 1994 and has a PhD in statistics from Carnegie Mellon University.

Dr. Murray Krahn, MD, MSc, FRCPC

Dr. Krahn is the Director of THETA (Toronto Health Economics and Technology Assessment Collaborative), the F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, Professor in the Faculties of Medicine and Pharmacy, University of Toronto, Senior Scientist the Toronto General Research Institute, and Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto. He is also an attending physician in the division of General Internal Medicine at the University Health Network, Toronto. Dr. Krahn’s research program focuses on the use of decision analytic methods to examine health policy and health decision making. Recent research includes the development of clinical policy models, disease-specific utility instruments, and use of large administrative datasets for developing longitudinal cost models. He was recently elected as the President of the Society for Medical Decision Making.

Dr. Tom Pickles, MD

Dr. Pickles is a Radiation Oncologist at the BC Cancer Agency, Vancouver, and Professor with Division of Radiation Oncology, Faculty of Medicine at University of British Columbia. His clinical interests include prostate cancer (active surveillance, and brachytherapy), lymphoid malignancies including radio-immunotherapy, and particle therapy. His research interests include doctor-patient communication, population-based outcomes analysis and PSA kinetics. He was the Chair of the BCCA Genito-Urinary Tumour Group 2000-2006.